Karkinos Healthcare had two of India’s wealthiest houses on its cap table — the Tata group and Reliance — and it still ran out of money. In April 2024 an unpaid invoice of ₹5.22 crore, owed to a lab-equipment supplier, was enough to drag the company into insolvency court, and by December 2024 the entire venture was sold for a fraction of its earlier worth.
The company set out to do something genuinely hard: take cancer detection and treatment out of a handful of metro hospitals and push it down to district towns through a “distributed” network. On the medicine, its model earned praise, including a mention in The Lancet Oncology. On the money, it burned cash faster than revenue could catch up — FY23 revenue of ₹22.17 crore sat against a net loss of ₹143.08 crore — and a business built to outlast cancer could not outlast its own balance sheet. This is the story of how a well-funded, well-intentioned oncology platform went from a ₹677 crore valuation to a distress sale under India’s bankruptcy code in under four years.
Quick facts
| Company | Karkinos Healthcare Private Limited (KHPL) |
| Founded | Incorporated 2020; clinical services began April 2021 (Idukki district, Kerala) |
| Founder(s) | R. Venkataramanan (Founder-CEO, ex-Managing Trustee, Tata Trusts) with co-founders including surgical oncologist Moni Abraham Kuriakose, Sundar Raman and Ravi Kant |
| Businesses | Distributed Cancer Care Network (DCCN) — screening, diagnostics, oncology labs, day-care and hospital care via hub-and-spoke partnerships |
| Latest reported FY revenue | ₹22.17 crore consolidated (FY23), up from ₹1.06 crore (FY22) |
| Latest reported FY loss | Net loss of ₹143.08 crore (FY23) |
| Listed | Private (never listed); entered insolvency (CIRP) in May 2024 |
| Last valuation / exit value | Last known valuation ₹677 crore; acquired out of insolvency for a resolution plan reported at ₹352 crore (press also cited ₹375 crore total consideration) |
| Key shareholders / acquirer | Backed by Ewart Investments (Tata Sons), Mayo Clinic and Reliance Digital Health; acquired by Reliance Strategic Business Ventures Ltd (RSBVL) in December 2024 |
What they do
Karkinos Healthcare sells cancer care as a coordinated network rather than as a single hospital. Its Distributed Cancer Care Network (DCCN) is a hub-and-spoke system meant to catch cancer earlier and treat it closer to where patients live — in district towns, not only in metros. The customers are twofold: patients (through screening camps, diagnostics and treatment) and the hospitals, labs and clinics it partners with, which plug into Karkinos’s protocols, oncology lab and technology stack.
- Cancer screening and early detection programmes, often run with community and government partners.
- Diagnostics, including what the company described as India’s first dedicated comprehensive oncology laboratory.
- Care delivery through partner hospitals plus its own planned facilities, coordinated by a digital oncology platform.
- Network reach: partnerships with roughly 60 hospitals across India by December 2023 (per insolvency and press disclosures).
The origin
The founding insight was about geography and timing. In India, most cancer is caught late and treated in a small number of tertiary hospitals concentrated in big cities, which pushes up cost and pushes down survival. Karkinos was built on the bet that a distributed network — screening and diagnostics at the edges, specialist oversight from the centre — could change both.
The person carrying that bet had unusual convening power. R. Venkataramanan spent more than 15 years inside the Tata group, ending as Managing Trustee of Tata Trusts, before founding Karkinos in 2020; he later became an advisor to the Chairman of Reliance Industries. That pedigree explains the cap table. The company assembled a founding group that mixed clinicians and operators — including surgical oncologist Moni Abraham Kuriakose, Sundar Raman and former Tata Motors managing director Ravi Kant — and started clinical services from Idukki district in Kerala in April 2021. The DCCN model was academic as much as commercial: it was cited in The Lancet Oncology as an approach to taking cancer care to communities.
The struggle years
Karkinos never had a quiet period long enough to reach scale. Two documented setbacks bracket its short life.
First, the money arrived slower than the plan assumed. According to a CARE Ratings note dated January 2024, the first tranche of equity was delayed by about two months and only completed in August 2022, which pushed back deployment into operations. Its flagship 150-bed multispecialty cancer hospital in Imphal, Manipur — estimated to cost around ₹150 crore — kept slipping: commercial operations were pushed from October 2023 to April 2024, with capex only 80–85% complete as of December 2023. Revenue that the company itself had projected at ₹195 crore for FY24 depended on facilities that were not yet open.
Second, the burn outran everything. FY23 consolidated revenue was ₹22.17 crore against a net loss of ₹143.08 crore. Headcount, which independent workforce tracker Revelio Labs estimates peaked near 800 in 2023, fell to roughly 542 by 2024 — a decline of about 13.7% — as the cash squeeze bit. The sequence that follows is not softened: a company backed by Tata and Reliance defaulted on a ₹5.22 crore supplier bill, and in April 2024 the operational creditor, Labindia Instruments Private Limited, took it to the National Company Law Tribunal.
The turning point
The single turning-point event was the insolvency filing and the sale that followed. On 21 May 2024 the Mumbai bench of the NCLT admitted Karkinos into the Corporate Insolvency Resolution Process (case CP(IB)/357(MB)/2024) and appointed Rajesh Sureshchandra Sheth as interim resolution professional. What had been a ₹677 crore-valued venture months earlier was now a distressed asset being valued for liquidation.
The numbers on each side of that event are stark. Admitted claims totalled about ₹202.16 crore — split as ₹37.59 crore secured financial, ₹65.12 crore unsecured financial and ₹99.45 crore operational. The registered valuers pegged fair value at ₹212 crore and liquidation value at just ₹167 crore. Against that, Reliance Strategic Business Ventures Ltd put forward a resolution plan that the Committee of Creditors approved with a 100% vote and the NCLT cleared on 9 December 2024. The plan promised to pay 100% of admitted claims (about ₹202 crore) plus roughly ₹150 crore of working capital — reported by insolvency trackers at ₹352 crore in total, while business press including The Ken framed the total consideration at ₹375 crore (about $39 million), structured as ₹10 crore of equity and ₹365 crore of optionally convertible debentures. Either way, the venture changed hands for well under half its last private valuation.
The money behind it
Karkinos raised heavily and from unusually blue-chip names for a company barely a year into operations. The funding shape:
- Founding round, 2021: a comprehensive oncology platform set up with about ₹110 crore, with angel backers reported to include Ratan Tata, Venu Srinivasan, Kris Gopalakrishnan, Ronnie Screwvala, Vijay Shekhar Sharma and Bhavish Agarwal (YourStory / company statements, 2021).
- Institutional backers: Ewart Investments, a Tata Sons subsidiary — the largest institutional investor; Mayo Clinic (USA); Reliance Digital Health Ltd; and early-stage fund Endiya Partners.
- Total raised: reported at roughly $58.2 million (CB Insights) and up to about $69 million across nine rounds (Tracxn) — sources differ, so treat this as a range.
- Last known valuation: about ₹677 crore (roughly $81 million), per CB Insights — the benchmark against which the eventual sale looked like a distress price.
What each backer changed: Tata’s Ewart Investments gave the venture institutional credibility and its founding capital; Mayo Clinic lent clinical and protocol validation; and Reliance moved from strategic investor (via Reliance Digital Health) to eventual owner through the insolvency process. A strategic partnership with Japan’s Rakuten Medical, announced in October 2021, was meant to bring novel cancer therapies to India.
How it makes money
Karkinos’s revenue model layered several streams on top of the network, but the economics were front-loaded with cost. Money in came from:
- Diagnostics and lab services: oncology-specific testing, the highest-frequency touchpoint in the model.
- Treatment and day-care revenue: chemotherapy and care delivered at partner facilities and planned Karkinos centres.
- Screening and detection programmes: often run with community, corporate or government partners.
- Network and technology enablement: plugging partner hospitals into Karkinos protocols, its oncology lab and its digital platform.
The part people get wrong is the timeline. A distributed cancer network is capital-heavy up front — labs, a hospital build, hub infrastructure, clinical hiring — while revenue only compounds as screening converts into diagnosis and treatment over years. CARE Ratings expected the company to post EBITDA losses at least through FY24 precisely because scaling revenue takes time. The margin, when it exists, sits in diagnostics and treatment throughput; but Karkinos was still building the throughput when the cash ran out. The FY22-to-FY23 jump from ₹1.06 crore to ₹22.17 crore shows the model could generate revenue — just not fast enough to cover a nine-figure annual loss.
The numbers
Three data points define the financial arc: revenue that was climbing off a tiny base, a loss far larger than revenue, and a projection that reality never reached. All figures are ₹ crore, consolidated where stated.
| Period | Revenue (₹ crore) | Profit / (loss) (₹ crore) |
| FY22 | 1.06 | Loss (EBITDA-negative; exact figure not disclosed) |
| FY23 | 22.17 | (143.08) |
| FY24 (company projection) | 195 (envisaged, not verified as achieved) | Expected EBITDA loss |
- Revenue grew roughly 20x from FY22 to FY23, but off a base near zero.
- The FY23 net loss of ₹143.08 crore was more than six times FY23 revenue.
- The ₹195 crore FY24 figure was the company’s own projection in a CARE Ratings note (January 2024); the insolvency that followed makes it unlikely it was met, so it is flagged here as unverified.
- Registered-valuer fair value at insolvency: ₹212 crore; liquidation value: ₹167 crore.
Where the money comes from
The revenue base was geographically dispersed by design and institutionally concentrated by ownership. The notable splits:
- By network: care flowed through roughly 60 partner hospitals across India by December 2023, plus company screening and diagnostic operations — a spread of small contributions rather than one large centre.
- By geography: clinical operations began in Kerala (Idukki) in April 2021, with a major planned anchor in the North-East — the 150-bed Imphal, Manipur hospital budgeted at about ₹150 crore.
- By ownership of capital: the surprise is how lopsided the backing was. Two of India’s largest conglomerates — Tata (via Ewart Investments) and Reliance — sat behind a company whose entire admitted claim book was only about ₹202 crore, and whose collapse was triggered by a ₹5.22 crore default.
The contradiction worth sitting with: deep-pocketed owners did not translate into resilience. Strategic investors are not obliged to keep writing cheques, and when fresh capital did not arrive on time, a company with marquee names on its cap table still could not clear a small operational bill.
The risks
The risks that sank Karkinos are concrete, and most are visible in its own disclosures and the insolvency record.
- Capex-versus-cashflow mismatch. The model demanded heavy up-front spending (labs, the Imphal hospital, network build) while revenue compounded slowly. CARE Ratings flagged EBITDA losses at least through FY24; a delayed equity tranche in 2022 and slipping hospital timelines turned a funding gap into a solvency event.
- Dependence on continued investor infusions. With a ₹143.08 crore FY23 loss on ₹22.17 crore of revenue, the business ran on external capital. When infusions slowed, even a ₹5.22 crore supplier default (to Labindia Instruments) was enough to trigger the CIRP — a small number toppling a large structure.
- Execution risk in a hard clinical market. Distributed cancer care requires simultaneously running screening, diagnostics, hospital construction and partner coordination across states. Any one delay — here, the Imphal hospital’s slip from October 2023 to April 2024 — starves the projected revenue the whole plan was underwritten on.
The takeaway
The transferable lesson is that a strong cap table is not the same as staying power. Karkinos had the names, the clinical validation and a model good enough for a Lancet mention — and it still failed, because the gap between capital-heavy build-out and slow-building revenue was wider than its runway. Marquee investors reduce the cost of raising money; they do not guarantee that the next round arrives on time, and they are free to let a business go into resolution rather than keep funding losses. For any founder building infrastructure-heavy, long-payback businesses, the discipline that matters is matching burn to committed, not hoped-for, capital — and treating even small operational liabilities as existential when the runway is thin. Karkinos’s assets and mission survived, now inside Reliance; the standalone company did not.
Frequently asked questions
What did Karkinos Healthcare do?
It ran a Distributed Cancer Care Network — a hub-and-spoke model for cancer screening, diagnostics and treatment designed to take oncology care beyond metros into district towns, in partnership with roughly 60 hospitals across India.
Why did Karkinos Healthcare go into insolvency?
It was cash-strained: FY23 revenue was ₹22.17 crore against a net loss of ₹143.08 crore. In April 2024 operational creditor Labindia Instruments took it to the NCLT over a ₹5.22 crore default, and the Mumbai bench admitted it into insolvency on 21 May 2024.
Who acquired Karkinos Healthcare?
Reliance Strategic Business Ventures Ltd, a Reliance Industries subsidiary. The NCLT approved its resolution plan on 9 December 2024 after the Committee of Creditors backed it with a 100% vote.
How much was Karkinos sold for?
The resolution plan was reported at about ₹352 crore — roughly ₹202 crore to pay 100% of admitted claims plus around ₹150 crore of working capital. Some business press cited a total consideration of ₹375 crore (₹10 crore equity plus ₹365 crore of convertible debentures). Its last known private valuation had been about ₹677 crore.
Who backed Karkinos Healthcare?
Institutional investors included Ewart Investments (a Tata Sons subsidiary), Mayo Clinic and Reliance Digital Health, alongside Endiya Partners; angel backers were reported to include Ratan Tata, Kris Gopalakrishnan, Ronnie Screwvala and others. Total funding was reported at roughly $58–69 million.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- CARE Ratings Ltd, press release on Karkinos Healthcare Private Limited — January 2024 (revenue FY22/FY23, FY24 projection, equity-infusion delay, Imphal hospital timeline).
- Digital Health News, “Reliance to Revive Karkinos Healthcare with INR 202 Cr Debt Infusion” — December 2024 (admitted claims breakdown, FY23 net loss, working-capital commitment, 60 hospital partners).
- Insolvency Tracker, “Reliance Industries arm buys Mumbai-based Karkinos Healthcare” — December 2024 (CIRP timeline, ₹352 crore plan, fair/liquidation value, CoC vote).
- Legal Era / Medical Buyer, NCLT approval of Reliance SBV resolution plan — December 2024.
- The Ken, “Why Reliance bought Tata-backed Karkinos for Rs 375 crore” — December 2024; India Infoline, “Reliance buys Karkinos Healthcare for ₹375 crore” — December 2024 (deal structure: ₹10 crore equity + ₹365 crore debentures).
- YourStory, “Tata group to invest ₹110 crore in Karkinos” — September 2021; Karkinos Healthcare investor and platform statements — 2021 (founding round, angels, DCCN, Kerala launch).
- CB Insights and Tracxn company profiles — 2026 (total funding ~$58–69M; last valuation ~₹677 crore).
- Revelio Labs, Karkinos Healthcare employee-count data — 2026 (headcount estimates 2022–2024).
- NCLT Mumbai, order in CP(IB)/357(MB)/2024; IBBI records (insolvency commencement 21 May 2024; IRP Rajesh Sureshchandra Sheth).
- Rakuten Medical press release — October 2021 (India partnership).
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.
